Galecto, Inc. (GLTO:NASDAQ) closed at $28.69 on March 9, 2026, down 0.76% on the day. The stock trades 25.1% below its 52-week high of $38.33 and 1,327.4% above its 52-week low of $2.01. Galecto, Inc. is part of the Health Care sector.
In 252 trading sessions since October 22, 2025, GLTO closed higher on 48 days (19%). Its best day was November 10, 2025 (+248.48%) and its worst was December 30, 2025 (-24.65%). The stock moved 10% or more in a single session 23 times. It opened at least 5% above the previous day's high 2 times.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
Find more stocks like GLTO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.